These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
516 related articles for article (PubMed ID: 28471952)
1. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. Wang Q; Liu F; Liu L Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis. Li XS; Li JW; Li H; Jiang T Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis. Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis. Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578 [TBL] [Abstract][Full Text] [Related]
5. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. Li J; Wang P; Xu Y PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis. Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF Front Immunol; 2018; 9():2077. PubMed ID: 30254644 [No Abstract] [Full Text] [Related]
8. Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study. Wang L J Ovarian Res; 2019 Apr; 12(1):37. PubMed ID: 31039792 [TBL] [Abstract][Full Text] [Related]
9. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794 [TBL] [Abstract][Full Text] [Related]
10. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis. Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941 [TBL] [Abstract][Full Text] [Related]
11. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153 [TBL] [Abstract][Full Text] [Related]
12. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature. Troiano G; Caponio VCA; Zhurakivska K; Arena C; Pannone G; Mascitti M; Santarelli A; Lo Muzio L Cell Prolif; 2019 Mar; 52(2):e12537. PubMed ID: 30443950 [TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295 [TBL] [Abstract][Full Text] [Related]
14. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y Front Oncol; 2019; 9():897. PubMed ID: 31620360 [No Abstract] [Full Text] [Related]
15. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. Yang H; Zhou X; Sun L; Mao Y Front Oncol; 2019; 9():47. PubMed ID: 30891423 [No Abstract] [Full Text] [Related]
16. PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis. Qin Y; Luan J; Zhou X; Li Y Biosci Rep; 2021 Mar; 41(3):. PubMed ID: 33704390 [TBL] [Abstract][Full Text] [Related]
17. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis. Zhang B; Liu Y; Zhou S; Jiang H; Zhu K; Wang R Int Immunopharmacol; 2020 Mar; 80():106214. PubMed ID: 31982822 [TBL] [Abstract][Full Text] [Related]
18. A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer. Hu XY; Zhang W; Hu Y; Zhang Y; Gong R; Liang JY; Liu L J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):313-320. PubMed ID: 27376797 [TBL] [Abstract][Full Text] [Related]
19. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099 [TBL] [Abstract][Full Text] [Related]
20. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis. Li S; Chen L; Jiang J Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]